Starling Oncology, Inc. (NASDAQ:STLNW)
| Market Cap | 4.42M-9.8% |
| Revenue (ttm) | 587.24M+38.4% |
| Net Income | -36.29M+44.9% |
| EPS | -0.30+55.8% |
| Shares Out | 99.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,505 |
| Open | 0.05 |
| Previous Close | 0.05 |
| Day's Range | 0.04 - 0.05 |
| 52-Week Range | 0.04 - 0.05 |
| Beta | 2.64 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 11, 2026 |
About STLNW
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$STLNW stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in STLNW holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by STLNW's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
STLNW Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New STLNW patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to STLNW from public contracts
Source: USAspending.gov
STLNW Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from STLNW’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score